Terms: = Lung cancer AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990 AND Treatment
27 results:
1. C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.
Lang C; Megyesfalvi Z; Lantos A; Oberndorfer F; Hoda MA; Solta A; Ferencz B; Fillinger J; Solyom-Tisza A; Querner AS; Egger F; Boettiger K; Klikovits T; Timelthaler G; Renyi-Vamos F; Aigner C; Hoetzenecker K; Laszlo V; Schelch K; Dome B
World J Surg Oncol; 2024 Feb; 22(1):57. PubMed ID: 38369463
[TBL] [Abstract] [Full Text] [Related]
2. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
[TBL] [Abstract] [Full Text] [Related]
3. Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.
Tsuboyama N; Wang R; Szczepanski AP; Chen H; Zhao Z; Shi L; Wang L
Oncogene; 2022 Apr; 41(15):2152-2162. PubMed ID: 35194152
[TBL] [Abstract] [Full Text] [Related]
4. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
[TBL] [Abstract] [Full Text] [Related]
5. Co-immunization with L-Myc enhances CD8
Chai D; Zhang Z; Jiang N; Ding J; Qiu D; Shi SY; Wang G; Fang L; Li H; Tian H; Yang J; Zhang Q; Zheng J
Cancer Sci; 2021 Sep; 112(9):3469-3483. PubMed ID: 34157192
[TBL] [Abstract] [Full Text] [Related]
6. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;
Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962
[TBL] [Abstract] [Full Text] [Related]
7.
Grunblatt E; Wu N; Zhang H; Liu X; Norton JP; Ohol Y; Leger P; Hiatt JB; Eastwood EC; Thomas R; Ibrahim AH; Jia D; Basom R; Eaton KD; Martins R; Houghton AM; MacPherson D
Genes Dev; 2020 Sep; 34(17-18):1210-1226. PubMed ID: 32820040
[TBL] [Abstract] [Full Text] [Related]
8. MYC, mycl, and MYCN as therapeutic targets in lung cancer.
Massó-Vallés D; Beaulieu ME; Soucek L
Expert Opin Ther Targets; 2020 Feb; 24(2):101-114. PubMed ID: 32003251
[No Abstract] [Full Text] [Related]
9. Tumor Heterogeneity Underlies Differential Cisplatin Sensitivity in Mouse Models of Small-Cell lung cancer.
Böttger F; Semenova EA; Song JY; Ferone G; van der Vliet J; Cozijnsen M; Bhaskaran R; Bombardelli L; Piersma SR; Pham TV; Jimenez CR; Berns A
Cell Rep; 2019 Jun; 27(11):3345-3358.e4. PubMed ID: 31189116
[TBL] [Abstract] [Full Text] [Related]
10. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell lung cancer Reveals Dynamic Insights into treatment Efficacy and Disease Relapse.
Almodovar K; Iams WT; Meador CB; Zhao Z; York S; Horn L; Yan Y; Hernandez J; Chen H; Shyr Y; Lim LP; Raymond CK; Lovly CM
J Thorac Oncol; 2018 Jan; 13(1):112-123. PubMed ID: 28951314
[TBL] [Abstract] [Full Text] [Related]
11. Family matters: How MYC family oncogenes impact small cell lung cancer.
Brägelmann J; Böhm S; Guthrie MR; Mollaoglu G; Oliver TG; Sos ML
Cell Cycle; 2017 Aug; 16(16):1489-1498. PubMed ID: 28737478
[TBL] [Abstract] [Full Text] [Related]
12. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract] [Full Text] [Related]
13. mycl is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
[TBL] [Abstract] [Full Text] [Related]
14. Transcription Factor NFIB Is a Driver of Small Cell lung cancer Progression in Mice and Marks Metastatic Disease in Patients.
Semenova EA; Kwon MC; Monkhorst K; Song JY; Bhaskaran R; Krijgsman O; Kuilman T; Peters D; Buikhuisen WA; Smit EF; Pritchard C; Cozijnsen M; van der Vliet J; Zevenhoven J; Lambooij JP; Proost N; van Montfort E; Velds A; Huijbers IJ; Berns A
Cell Rep; 2016 Jul; 16(3):631-43. PubMed ID: 27373156
[TBL] [Abstract] [Full Text] [Related]
15. Small-cell lung cancers in patients who never smoked cigarettes.
Varghese AM; Zakowski MF; Yu HA; Won HH; Riely GJ; Krug LM; Kris MG; Rekhtman N; Ladanyi M; Wang L; Berger MF; Pietanza MC
J Thorac Oncol; 2014 Jun; 9(6):892-6. PubMed ID: 24828667
[TBL] [Abstract] [Full Text] [Related]
16. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
[TBL] [Abstract] [Full Text] [Related]
17. External Qi of Yan Xin Qigong induces cell death and gene expression alterations promoting apoptosis and inhibiting proliferation, migration and glucose metabolism in small-cell lung cancer cells.
Yan X; Li F; Dozmorov I; Frank MB; Dao M; Centola M; Cao W; Hu D
Mol Cell Biochem; 2012 Apr; 363(1-2):245-55. PubMed ID: 22160803
[TBL] [Abstract] [Full Text] [Related]
18. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Zhong L; Shen H; Huang C; Jing H; Cao D
Toxicol Appl Pharmacol; 2011 Aug; 255(1):40-7. PubMed ID: 21640744
[TBL] [Abstract] [Full Text] [Related]
19. Retinoic acid-mediated growth inhibition of small cell lung cancer cells is associated with reduced myc and increased p27Kip1 expression.
Weber E; Ravi RK; Knudsen ES; Williams JR; Dillehay LE; Nelkin BD; Kalemkerian GP; Feramisco JR; Mabry M
Int J Cancer; 1999 Mar; 80(6):935-43. PubMed ID: 10074929
[TBL] [Abstract] [Full Text] [Related]
20. Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients.
Yamamoto A; Shimizu E; Ogura T; Sone S
Int J Cancer; 1996 Aug; 69(4):283-9. PubMed ID: 8797869
[TBL] [Abstract] [Full Text] [Related]
[Next]